Navigation Links
Experimental RNA-based drug kills prostate cancer cells effectively and safely

Acting as a genetic Trojan horse, an experimental RNA-based drug -- the first of its kind -- tricks its way into prostate cancer cells and then springs into action to destroy them, while leaving normal cells unarmed.

The drug, developed at Duke University Medical Center, uses one type of genetic material, called targeting RNA, to enter cancer cells, and another type, called silencing RNA, to stop the expression of a protein that keeps the cells alive.

In tests in mice with prostate cancer, the drug shrank the size of their tumors by half, while the tumors in control mice that did not receive the drug continued to grow, said study co-author Bruce Sullenger, Ph.D., director of Duke's Translational Research Institute and chief of the Division of Experimental Surgery.

The mice showed no side effects from the treatment, Sullenger said.

"This study represents the first step in creating an RNA-based drug for cancer," said lead author James McNamara, Ph.D. a postdoctoral fellow in experimental surgery. "It provides a 'proof of principle' that an entirely RNA-based drug can work with minimal side effects, and it shows it is possible to overcome many of the obstacles that have hampered the development of RNA-based drugs."

The study is reported in the August 2006 issue of Nature Biotechnology, which is now available online. The research was funded by the National Institutes of Health.

Duke has filed a provisional patent application on the technology, according to the researchers.

"Scientists have made numerous attempts to transform silencing RNAs into natural anticancer agents, but such development has been challenging," said Paloma Giangrande, Ph.D., co-leader of the study and an assistant research professor in experimental surgery.

Scientists have encountered major obstacles when trying to deliver silencing RNAs to tumors, Giangrande said. Previous RNA-based drugs have been nonspecific, targeting all cel
'"/>

Source:Duke University Medical Center


Page: 1 2

Related biology news :

1. NIAID Initiates Trial of Experimental Avian Flu Vaccine
2. Experimental shingles vaccine proves effective in nationwide study
3. Experimental vaccine protects nonhuman primates when given after exposure to Marburg virus
4. Experimental TB drug effective against resistant and latent mycobacterium tuberculosis
5. Experimental drug reverses key cognitive deficits, pathology in Alzheimers
6. Experimental vaccine protects lab animals against several strains of H5N1
7. Experimental vaccine protects mice against deadly 1918 flu virus
8. Experimental cancer drugs counter muscle deterioration seen in muscular dystrophy
9. Experimental vaccine given during pregnancy reduces stillbirths from common virus
10. Study: Harmless virus kills some cancers
11. VCU study shows hormone-like molecule kills cells that cause inflammation in allergic disease
Post Your Comments:
(Date:7/30/2014)... iodine-125 (125I) in cancer treatment has been shown ... are critical for neural transmission between the peripheral ... colleagues from Institute of Radiation Medicine, Chinese Academy ... be implanted into rat dorsal root ganglia (DRG) ... with different radioactivity (0, 14.8, 29.6 MBq) were ...
(Date:7/30/2014)... , July 30, 2014 The Nano-Bio ... United States Air Force Research Laboratory (AFRL), has ... Binghamton University to develop electronics ... (HPM). The $425,000 project, with contributions from the ... i3 Electronics, Inc. ( Endicott, N.Y. ...
(Date:7/29/2014)... methods and applications for imaging and manipulation of the ... were the inspiration behind Neurophotonics , a new ... optics and photonics. , The first issue coincides with ... States, and a special section features articles that lay ... impact that optics and photonics will have on advancing ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Awards Funding to Binghamton University for Development of Electronics and Biometric Sensor Platforms 2Nano-Bio Manufacturing Consortium Awards Funding to Binghamton University for Development of Electronics and Biometric Sensor Platforms 3SPIE launches Neurophotonics journal with special section on BRAIN Initiative 2SPIE launches Neurophotonics journal with special section on BRAIN Initiative 3
... Mixing commonly used antibiotics with common blood ... pressure) and induce shock in older patients, requiring ... CMAJ ( Canadian Medical Association Journal ) ... antibiotics (erythromycin, clarithromycin and azithromycin) are among the ...
... Company part owned by Shell has announced plans ... of the Western North Pacific gray whale population. ... population exist today, and their primary feeding habitat off ... besieged by multiple oil and gas exploration and development projects. ...
... January 16, 2011 (BRONX, NY) In ... gene expression influences human disease, scientists at Albert ... for the first time ever successfully visualized single molecules ... cells. The scientific achievement is detailed in the January ...
Cached Biology News:Oil giant plans new platform near feeding ground of critically endangered whale 2Oil giant plans new platform near feeding ground of critically endangered whale 3
(Date:7/30/2014)... PA (PRWEB) July 30, 2014 Vycom ... family of products, designed to meet Factory Mutual (FM) ... equipment materials such as wet benches, process tools, fume ... worker safety and damage to semiconductor wafers used in ... provides a flame-retardant PVC solution with excellent workability and ...
(Date:7/30/2014)...  Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), is ... technologies are used to discover, develop, manufacture and ... bio-based chemical, biopharmaceutical and industrial enzyme industries, announced ... Vice President and Chief Financial Officer. Tom will ... technology operations for Dyadic and will succeed ...
(Date:7/30/2014)... , July 30, 2014  AtheroNova Inc. (OTCBB: ... and development of compounds to safely regress atherosclerotic ... announces that its partner, CardioNova, has accomplished first ... trial with AtheroNova,s lead compound, AHRO-001.  This Phase ... AHRO-001 Phase 1 safety trial completed in February ...
(Date:7/30/2014)... Hartford, CT (PRWEB) July 30, 2014 ... economic development organization based in East Hartford, Conn., was ... on Phase II of a project that will determine ... facility in rural north-central Connecticut. USDA Rural Development provided ... (RBEG) program for the second phase of the feasibility ...
Breaking Biology Technology:Vycom Announces Flametec® Thermax PVC (FM4910 Listed) For a Variety of Clean Room Applications with Excellent Workability and Aesthetics 2Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 2USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 3
... VANCOUVER , June 30 /PRNewswire/ - Sirius Genomics, ... has been appointed Senior Director of Business Development. , ... "Sirius Genomics is on ... Kam,s extensive background in partnering with both global pharmaceutical and medical ...
... Tekscan, Inc. ... the traditional pin connection, Tekscan is now offering a lower-cost termination method to enable OEM ... , ... -- Tekscan, Inc. announces a new lower-cost connection option for its custom FlexiForce® sensors ...
... A ... users sports performance , ... Denmark (PRWEB) June 30, 2010 -- Recent researches have found scientific evidence that proves ... researchers from Denmark revealed that the level of enhancement of performance due to the use ...
Cached Biology Technology:Sirius Genomics Announces Appointment of Senior Director of Business Development 2Lower-Cost ZIF and LIF-Compatible Connection Option for Tekscan Custom Force Sensors 2Recent Study Reports Reveals that HGH May Aid Performance 2
... SeeDNA co-precipitant, 250 ... pink color ensures easy ... nucleic acid recovery.Chemically inert, ... biology applications.Simple 5-minute protocol. ...
Can be used for the quantitative recovery of small amounts of nucleic acids within dilute solutions. 5mg/ml...
Request Info...
Recombinant Mouse TGF-beta RII/(human) Fc Chimera, CF...
Biology Products: